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Cancer is a consequence of multicellularity due to the fact 
that the cellular genome is under continuous attack from 
a variety of environmental or metabolic genotoxic agents. 
Moreover, the DNA replication machinery is not perfect 
[1]. Hence, the development of mutations in cells is both a 
natural and artificial – for example, in the case of smoking 
– process. The finite number of cells and the randomness 
of cell mutation events lead to a stochastic cell dynamics 
encompassing  several  scenarios,  including  extinction  of 
acquired  clonal  stem  cell  disorders,  which  explains, 
among other things, spontaneous resolution of diseases.
Although  many  mutations  are  either  neutral  [2]  or 
cytotoxic,  some  mutations  may  increase  the  risk  of 
malignant  transformation  in  which  the  cell  loses 
regulated growth control giving rise to a clone that may 
threaten  the  life  of  the  organism  [3,4].  The  risk  of 
acquiring mutations depends on the mutation rate, the 
population of cells at risk, and the average lifetime of the 
cell  since  it  is  unlikely  that  multiple  simultaneous 
mutations  occur  in  the  same  cell  [5,6].  Tissues  have 
evolved an architecture where most cells have a relatively 
short lifetime and undergo continuous turnover, and this 
mitigates the accumulation and retention of mutant cells 
[7]. At the root of this process are the stem cells that are 
able  to  maintain  tissue  integrity  because  of  a  dual 
phenotypic characteristic: self-renewal and production of 
progeny that can differentiate into various cell lineages 
that  together  constitute  tissues  and  organs.  One  can 
visualize tissues as having a tree-like organization of cells 
with stem cells at one extreme and mature, non-dividing 
cells at the other extreme [8]. Intermediate cells divide, 
often at relatively high rates, but live for relatively short 
periods of time. Although mutations can occur at every 
level of this cell hierarchy, the relatively short lifetime of 
more mature cell stages means that, in effect, the real risk 
of long-lasting oncogenic mutations is restricted to the 
small population of stem cells and early progenitor cells 
that  maintain  a  given  tissue.  This,  in  turn,  effectively 
reduces the probability of the occurrence of mutations, 
given the small population of cells at risk, despite the fact 
that a mutation arising in a stem cell can persist for a long 
time. It is important to point out that the relevance of a 
mutation  is  cell  context-dependent  –  a  mutation  in  a 
gene that is not expressed in a cell is of no consequence 
to that cell but expression of the gene in more committed 
cells,  downstream  of  the  cell  that  is  the  source  of  the 
mutation,  may  lead  to  a  phenotype  associated  with 
disease [9,10]. The natural history of such mutations is 
the focus of this article. We put forward a possible role of 
stochastic effects on the generation and fate of mutations 
acquired  by  stem  cells.  Other  investigators  have  also 
explored the impact of randomness on the fate of tumor 
cells [11,12]. We will provide some examples from several 
well-known  blood  disorders  to  illustrate  the  concepts 
that will be discussed.
Stochastic dynamics of stem cells
For practical purposes, it is generally accepted that one 
can consider the number of stem cells contributing to a 
given tissue (for example, hematopoiesis) as constant (N), 
especially over short periods of time. As stated before, 
the probabilistic behavior of the finite cell population is 
the basis of a stochastic dynamics that can be captured by 
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cell will be selected for reproduction with a probability 
that is dependent on its frequency within the population 
and  also  proportional  to  its  reproductive  fitness  (r). 
Reproduction will increase the net size of the population 
by one cell, so one must exit the pool if the population is 
to remain constant. It is assumed that this cell is selected 
randomly  and  that  it  has  started  the  path  of 
differentiation  in  the  sense  that  such  a  cell  will  never 
again  be  selected  to  reproduce  in  the  stem  cell  pool. 
Initially, we only have N normal cells and whenever one is 
selected to divide, there is a probability m that one of the 
daughter cells will acquire a mutation in a specific gene 
(Figure  2a).  Therefore,  with  probability  1 – m,  no 
mutation will occur. If a mutation occurs, there will then 
be a new population of (mutant) cells to consider (M) 
that can also be selected to divide. When mutant cells 
divide,  they  give  rise  to  more  mutant  cells  since  the 
probability of correcting a mutation is virtually zero [5,6]. 
Mutations can alter the relative reproductive fitness of 
cells – while the relative fitness of normal cells can be 
defined to be one, mutant cells will have a relative fitness 
r (Figure 2a); r < 1 means a lower relative fitness, r > 1 
represents a higher relative fitness and r = 1 means that 
the mutation gives no reproductive advantage compared 
to  the  remaining  wild-type  population.  Therefore, 
assuming that mutant cells are present, the probability 
Figure 1. The basic principles of the Moran process. The Moran process assumes that, over short periods of time, the total population of cells 
is constant. (a) To start with, a cell is selected for reproduction. Selection is dependent on the frequency of the cell in the population and its 
reproductive fitness (r). (b) The cell divides, and the number of cells increases by one. (c,d) Therefore, another cell is selected for export (c), which 
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Figure 2. Evolutionary dynamics under the Moran process. 
(a) When normal cells divide, there is a probability m that one of the 
daughter cells will have a mutation, while with probability 1 – m no 
mutation occurs. Mutant cell replication increases the number of 
mutant cells – no back mutations are allowed. (b) Cells have a relative 
reproductive fitness r compared to normal cells, which have a fitness 
1. (c) The probability that a cell is chosen for reproduction (PM for 
mutant and PN for normal cells) is dependent both on its frequency 
and its relative fitness. If j is the number of mutant cells at that time 
and N is the total number of cells present, the number of normal cells 
will be N – j. Since a cell has to be chosen at any time – if a mutant 
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where j denotes the number of mutant cells present at 
that time (Figure 2c). This probability will vary with time 
and increases as the population of mutant cells expands. 
Since  at  any  time  point  a  cell  has  to  be  chosen  for 
reproduction, the probability of selecting a normal cell 
for replication is given by the equation below [13]:
PN(j) = 1 – PM(j)
If this process continues for a very long time, the result 
will  ultimately  be  a  state  where  either  all  the  cells  are 
normal (extinction, Figure 3a) or all the cells are mutated 
(fixation,  Figure  3d).  It  is  possible  to  calculate  the 
probability that the mutant population will reach fixation, 
although the time it will take to reach this state may be 
very long. For example, normal hematopoietic stem cells 
(HSCs) on average divide once per year [14]. Given that 
approximately  400  HSCs  are  actively  involved  in 
hematopoiesis [15,16], one can consider that, on average, 
approximately one cell is chosen daily for reproduction 
[14].  Therefore,  one  can  imagine  that  the  process  to 
fixation is generally slow and probably unreachable in the 
lifetime of a human [17] unless the reproductive fitness of 
the mutant is very high, a characteristic that appears to 
be unusual [18]. This is important – it is well known that 
in  acquired  HSC  disorders  such  as  chronic  myeloid 
leukemia  (CML),  leukemic  stem  cells  will  generally 
coexist  with  normal  stem  cells  [19].  In  paroxysmal 
nocturnal  hemoglobinuria  (PNH),  another  clonal  stem 
cell disorder, there is also evidence for the coexistence of 
normal  and  mutant  clones  [20].  Finally,  many  patients 
with acute leukemia have been cured with chemotherapy 
alone, a feat that would be impossible if the normal HSCs 
were  obliterated  by  the  malignant  clone.  Hence, 
neoplastic  diseases  due  to  acquired  mutations  are 
generally characterized by co-existence and competition 
of  normal  and  mutant  stem  cells,  and  therefore  the 
interesting dynamics occur before fixation.
In several bone marrow disorders, disease requires that 
a specific threshold of mutant stem cells is surpassed: at 
Figure 3. The outcomes of Moran dynamics. (a,d) Assuming that a mutant stem cell is present, stochastic dynamics will predict extinction of 
the mutant cell (a) or fixation (d). (b,c) However, fixation may require a long time – hence the clone may persist in a latent state (no disease) (b) or 
could reach a threshold leading to a disease state (c). At any of these steps, stochastic extinction is still possible, although less likely as the burden 
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diagnose acute leukemia, and 10% clonal plasma cells are 
required  to  diagnose multiple  myeloma  [21]. Although 
these  thresholds  are  somewhat  artificial,  they  are 
meaningful at the clinical level, and they surely correlate 
with a corresponding burden of mutated stem-cells at the 
time  diseases  are  diagnosed.  We  can  use  the  Moran 
process  to  define  the  probability  that,  at  least  once,  a 
mutant stem cell can expand to reach a defined threshold 
required to cause disease. This is again a function of the 














where M0 is the initial number of mutant cells and M1 is 
the number of mutant cells needed to reach the threshold 
[13]. This probability is independent of the size of the stem 
cell compartment and depends only on the relative fitness 
of the mutant population versus normal cells. The above 
model considers that the HSC pool is homogenous and 
cells divide symmetrically – differentiation is the result of 
selection of a cell to differentiate. On average, this behavior 
gives  the  same  qualitative  results  as  a  more  elaborate 
model where the symmetry or lack thereof of stem cell 
replication  is  taken  into  consideration.  A  model  that 
captures  these  various  dynamics  has  been  described  in 
detail elsewhere [22]. Assuming that a threshold has to be 
reached to give rise to disease, it is possible to determine 
the probability distribution functions for the time it will 
take to reach that threshold as a function of the relative 
fitness  advantage  due  to  a  specific  mutation  (Figure  4). 
One can make two observations: (i) the probability that the 
threshold  is  reached  early  in  time  grows  as  the  fitness 
advantage  increases;  and  (ii)  the  width  of  these 
distributions is inversely related to the fitness advantage. 
For  a  small  fitness  advantage,  the  time  distribution  for 
reaching  the  threshold  is  very  wide,  rendering  any 
summary estimates such as the average meaningless.
The  Moran  model  assumes  homogenous  mixing  of 
populations;  that  is,  the  spatial  distribution  of  the 
population is not considered. This means that one cell in 
a specific place reproduces and a cell elsewhere is chosen 
for death, a scenario perhaps easiest to accept in small 
populations of stem cells, such as in an individual colonic 
crypt [23]. However, the Moran process may also be of 
relevance  to  hematopoiesis,  where  stem  cells  are 
distributed  throughout  the  bone  marrow,  since  HSCs 
appear  to  be  coupled  chemically  and  perhaps  even 
neurologically [24,25], which may allow them to function 
as a homogenous population. Perhaps the best example 
of  this  tight  coupling  is  the  constant  frequency  of 
oscillations in a disease known as cyclic hematopoiesis 
(neutropenia).  In  this  condition,  the  neutrophil  count 
(and that of other types of cell) oscillates with a regular 
frequency (19 to 21 days) for the lifetime of the person 
[26]. For this process to be sustained, tight coupling of 
cellular  reproduction  in  time  must  be  present,  even 
though the cells are scattered in space – otherwise the 
oscillations  will  dissipate  as  cell  reproduction  loses 
synchronization  [10].  On  the  other  hand,  Moran 
dynamics  introduced  here  does  not  capture  the 
symmetric or asymmetric division of individual cells and 
therefore  the  process  can  only  provide  an  average 
account of the population dynamics. However, one can 
argue that it is the population that evolves and not the 
individual  cell(s).  An  analysis  of  the  impact  of  the 
symmetry of cell division on mutant clone dynamics has 
been described elsewhere [22].
Application of stochastic dynamics to disease 
modeling: clonal expansion
Reproduction  of  mutant  cells  leads  to  their  expansion 
into  a  clone.  How  frequently  the  cells  are  chosen  for 
replication  depends  on  their  relative  frequency  in  the 
population  and  on  their  relative  reproductive  fitness 
(Figure 2b,c). Although cells with a higher relative fitness 
will be more likely to be selected for reproduction, it does 
not follow that cells with neutral or even reduced relative 
fitness  cannot  expand.  Although  the  probability  that  a 
neutral clone will expand to reach a given threshold is 
small, this can happen and may lead to disease. The best 
example is PNH, an acquired clonal HSC disorder due to 
a mutation in the PIG-A gene. The ultimate result of this 
Figure 4. Probability distribution functions to reach the 
diagnostic threshold. Stochastic simulations of Moran dynamics, 
recording the probability that the mutant clone reaches the 
diagnostic threshold at a given time after the occurrence of the 
mutation (diagnosis is here defined as at least 20% of the cells being 
mutated) as a function of the fitness advantage (r) of mutated cells. 
The smaller the fitness advantage of mutated cells, the longer it takes 
for the threshold to be reached, and the smaller the probability of 
reaching the threshold in a given time.
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sitol (GPI)-anchored proteins from the plasma membrane 
of cells (for example, CD55 and CD59), which renders 
red  blood  cells  unusually  sensitive  to  complement-
mediated  lysis,  thus  leading  to  intravascular  hemolysis 
and hemoglobinuria [27]. To date, no fitness advantage 
has  been  identified  in  cells  with  this  mutation 
(summarized  in  [28]).  We  have  shown  that  a  Moran 
model of HSC dynamics can predict various aspects of 
the natural history of PNH. The model assumes that the 
PIG-A mutation gives no fitness advantage to the HSC 
(neutral  drift).  We  introduced  in  the  model  (i)  the 
number  of  active  HSCs  that  are  contributing  to 
hematopoiesis,  (ii)  the  rate  of  replication  of  the  cells 
(approximately  once  per  year)  [16],  (iii)  the  known 
mutation rate in the PIG-A gene [29] and an acceptable 
threshold of mutant cells needed to cause disease [30]. 
Extended simulations of the process lead to predictions 
of the incidence of PNH in the general population and an 
average clone size within patients [28] in good agreement 
with  available  data.  Therefore,  clonal  expansion  by 
neutral drift can lead to disease, and perhaps explain why 
a disease such as PNH is so rare.
Expression  of  BCR-ABL  in  HSCs  leads  to  a  disease 
resembling chronic phase CML in experimental animals, 
suggesting that this oncogene is enough to explain the 
early chronic phase of the disease [31,32]. Modeling of 
the dynamics in CML suggests that BCR-ABL does not 
give a fitness advantage to the mutant stem cells [33-35]. 
This is now supported by direct and indirect experimental 
evidence [36,37]. Neutral drift implies that expansion of 
this population of CML stem cells will generally be slow 
and, as a consequence, the clone size will be small. In 
addition, there is a reasonable chance that the mutant 
stem cell clone will be stochastically eliminated [34]. Can 
such an event happen? Currently, patients with CML are 
treated with tyrosine kinase inhibitors, such as imatinib 
or nilotinib, that have no detectable effect on the CML 
stem  cells  [38].  Therefore,  it  has  been  assumed  that 
imatinib  cannot  cure  patients  with  this  disease  and 
patients should continue therapy indefinitely. However, 
stochastic extinction implies that imatinib can effectively 
cure some patients even without directly killing the CML 
stem  cells.  In  such  cases,  therapy  could  be  stopped 
without relapse of the disease. The major issue here is 
how long treatment should continue since one wants to 
be  certain  that  the  CML  stem  cells  have  been 
stochastically  eliminated  before  withdrawing  therapy. 
This  issue  has  been  addressed  using  a  computational 
model  of  CML  dynamics  under  imatinib  therapy  that 
takes into consideration stochastic dynamics within the 
stem cell pool. Starting from diagnosis, it may take up to 
5 years or more for the patient to reach a major molecular 
response  (>4  log  reduction  in  disease  burden)  and 
probably  longer  to  achieve  a  complete  molecular 
response. If therapy were continued for another 2 years 
after reaching this threshold, the probability of relapse 
becomes  small  [34]  (below  2%).  Recent  data  from  the 
French CML group suggests that indeed some patients 
may be able to stop therapy without relapsing, although 
longer follow-up is needed [39].
Stochastic dynamics of latency
It  is  not  uncommon  to  find  mutations  in  disease-
associated genes in healthy adults. For example, almost 
every  human  has  a  PIG-A  mutated  clone  [40].  Small 
clones  harboring  the  Philadelphia  chromosome  and 
expressing BCR-ABL have been described [41], and the 
JAK2V617F mutation, which is normally associated with 
chronic myeloid neoplasms, may be present in up to 1% 
of the population [42,43]. The origins, implications and 
dynamics  of  these  observations  have  been  discussed 
elsewhere  [44].  PIG-A  mutant  clones  may  disappear 
during  follow  up  [40]  or  fluctuate  stochastically  but 
others may persist without detectable evolution, as has 
been reported in individuals with JAK2V617F essential 
thrombocythemia [45]. Latency is therefore compatible 
with  stochastic  behavior  within  the  stem  cell  pool 
(Figure 4). However, there is at least one other scenario 
that  can  explain  latency.  In  many  if  not  all  tumors, 
acquisition of the full cancer phenotype may require the 
serial  accumulation  of  gain-of-function  mutations  in 
oncogenes  and  loss-of-function  mutations  in  tumor 
suppressor  genes,  as  well  as  epigenetic  changes.  For 
example, the adenoma to carcinoma sequence in colon 
cancer is associated with mutations in APC, K-RAS, and 
TP53 amongst others [46]. Hence, it is possible that a 
transient  clone  may  arise  harboring  one  of  these 
mutations  but,  without  the  accumulation  of  additional 
mutations, it may not grow enough to be detectable, thus 
remaining a latent clone.
Stochastic extinction
The  stochastic  dynamics  associated  with  the  Moran 
process  predicts  the  possibility  of  extinction  of  any 
mutant  clone,  irrespective  of  its  relative  fitness.  This 
phenomenon,  however,  becomes  quite  likely  when  the 
mutation either gives a relative fitness disadvantage or is 
neutral.  It  is  important  to  remember  that  even  for 
mutations that increase the reproductive fitness of the 
cell, extinction is still possible. One can computationally 
show that even for a mutation that increases the relative 
fitness of cells by a factor of two, which, in evolutionary 
terms,  constitutes  a  very  high  fitness  advantage,  the 
probability of extinction of the mutant cell is still about 
50%  [13].  Of  course,  as  the  cell  expands  into  a  clone, 
extinction  becomes  less  likely,  explaining  why  most 
tumors do not resolve without therapy.
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curiosity: there is evidence that clonal extinction occurs 
in  vivo.  Let  us  discuss  several  examples.  First,  healthy 
individuals have been shown to have small clones with 
the Bcr-Abl oncogene but not necessarily develop CML 
[41]. In some of these individuals, the clone will disappear 
in time without any specific therapy. Another example is 
patients who have been diagnosed with myelodysplastic 
syndromes,  a  group  of  clonal  preleukemic  stem  cell 
disorders, that in some cases resolve without any specific 
therapy directed at the malignant clone [47]. One of the 
best  examples  of  clonal  extinction  is  that  observed  in 
transient  myeloproliferative  disorder  (TMD),  which 
occurs in a significant fraction of children with Down’s 
syndrome and is often diagnosed at or soon after birth 
[48,49].  The  malignant  cells  appear  to  have  a  very 
‘primitive origin’, implying mutations in early progenitor 
cells if not in the HSCs. In the vast majority of patients, 
the  condition  resolves  with  minimal  or  no  therapy, 
although it is lethal in some cases. One of the fascinating 
features  about  PNH  is  that  the  disease  sometimes 
resolves in the absence of therapy (other than allogeneic 
bone  marrow  transplantation)  that  directly  targets  the 
mutant  clone.  The  frequency  of  this  spontaneous 
resolution  is  in  the  range  of  12  to  15%  and  has  been 
confirmed  using  both  the  Ham’s  test  (a  test  of  the 
sensitivity of red cells to complement-mediated lysis) and 
the more sensitive flow cytometry assay (which directly 
determines the fraction of cells that belong to the PNH 
clone  by  detection  of  CD55  and  CD59  positive  and 
negative  cells)  [50,51].  While  no  clear  explanation  has 
been provided for this phenomenon, our own simulations 
of  HSC  dynamics  predict  that  clonal  extinction  after 
diagnosis can occur in about 12% of patients, in excellent 
agreement with epidemiological data [28].
We wish to remind the reader that, in principle, other 
potential  explanations,  alternative  to  stochastic 
extinction, could exist for the disappearance of mutant 
clones.  For  example,  our  model  does  not  consider  the 
potential impact of immune surveillance and elimination 
of tumor cells by the immune response. There is some 
evidence for this phenomenon, especially in the context 
of  allogeneic  stem  cell  transplantation.  However, 
elimination  of  a  mutant  clone  due  to  an  autologous 
immune attack is also possible. These scenarios are not 
mutually exclusive and perhaps either occurs in a subset 
of patients.
Conclusions
Stochastic behavior is an intrinsic aspect of life – both at 
the  cellular  and  organismal  level.  Acquisition  of 
mutations and the evolution of clones are processes that 
are  highly  sensitive  to  stochastic  effects  since  the 
population  under  consideration  is  often  small. 
Mathematically, it is as if cells play dice – many times the 
impact  of  such  a  gamble  is  inconsequential,  at  other 
times  it  leads  to  the  loss  of  a  particular  cell  lineage. 
Unfortunately, there are times when acquired mutations 
lead to clonal expansion and disease. Depending on the 
fitness  of  the  mutant  clone,  stochastic  extinction  is 
possible, especially when the population is small and the 
relative fitness advantage minimal compared to normal 
cells but also even when the population is not small or 
the  fitness  advantage  is  significant.  It  is  in  these 
circumstances that chance may play a role in cure versus 
disease. Reduction in disease burden to low levels could, 
in  principle,  lead  to  clonal  extinction,  especially  if  the 
fitness advantage of the mutant cells can be reduced by 
therapy.
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